EHC Partners With EUPATI To Enhance Education And Research For European Patients

EHC Partners With EUPATI To Enhance Education And Research For European Patients

BRUXELLES, Belgium, 30/06/2025 – The European Haemophilia Consortium (EHC) is excited to have signed a partnership with the European Patients’ Academy of Therapeutic Innovation (EUPATI).

The EHC represents approximately 120.000 people diagnosed with rare bleeding conditions such as haemophilia, von Willebrand Disease (VWD), and other extremely rare bleeding disorders. The EHC draws on the knowledge of patients, healthcare professionals, the scientific community, the European institutions, and the pharmaceutical industry to share expertise within Europe. The EHC also collaborates closely with other European patient organisations to ensure a strong collective voice for people with rare bleeding disorders.

This partnership aligns with EUPATI’s vision and mission to provide education, information and opportunities for collaboration for patients and the scientific community to support a better health ecosystem. Both organisations operate in a multi-stakeholder structure, making the union a natural fit.

Maria Dutarte, EUPATI Executive Director, states how EUPATI is delighted to “join the EHC in partnership and support their important mission to stimulate research in all fields related to haemophilia and related rare bleeding disorders, through training and knowledge building in medicines R&D. EHC’s vast network, representing over 120,000 patients and their long-term experience in multi-stakeholder collaboration with patients, healthcare professionals, the scientific community, the European institutions, and the pharmaceutical industry makes them a strong addition to the EUPATI family.”

Olivia Romero Lux, EHC Chief Executive, adds: “We’re proud to announce a new partnership between the EHC and EUPATI! This collaboration marks an exciting step forward in our shared mission to empower and support European patients, especially those living with rare bleeding disorders. Together, we’ll strengthen patient education, advocacy, and engagement across Europe to ensure that patient voices are heard and reflected in research, policy, and care.”

About EUPATI: The European Patients’ Academy on Therapeutic Innovation (EUPATI) is a non-profit foundation with a multi-stakeholder structure that provides patients and the public with accessible, well-structured, and reliable education about the lifecycle of medicines research and development, while also upskilling professionals on meaningful patient involvement.

About EHC: The European Haemophilia Consortium (EHC) is an international non-profit organisation representing 48 national patient organisations for people with rare bleeding disorders located in the World Health Organisation (WHO) European region, including 27 Member States of the European Union and most Member States of the Council of Europe.